MedinCell SA

Teva Pharmaceutical Industries Ltd. is making progress on its “Pivot to Growth” strategy and is one step closer to adding a new medicine to its innovative portfolio – a novel long-acting subcutaneous

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Partners With MedinCell On Up To

Teva Pharmaceutical Industries Ltd. believes it can build a sizable commercial franchise out of its newly approved long-acting antipsychotic Uzedy (risperidone). During Teva’s first quarter sales and

Teva expects to launch its Uzedy long-acting injectable risperidone product within weeks after receiving a long-awaited US Food and Drug Administration approval for the 505(b)(2) hybrid schizophrenia